NewsRoom Articles - Page 59 of 154 - PsychedelicNewsWire (PNW)

WednesdayMay 11, 2022 11:57 am

Study Indicates People Are Cautious About Psilocybin Therapy, More Awareness Needed

A new study has found that individuals are cautious about the use of psilocybin-assisted psychotherapy in the treatment of depression. Psilocybin is an active chemical found in magic mushrooms. This mind-altering compound may influence how individuals experience the world by inducing changes in the sense of self as well as a user’s perception of time, sensory perception and mood. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy can bring about improvements for patients afflicted by depression. The researchers’ objective was to look into individuals’ perceptions of psilocybin-assisted therapy in comparison to their perceptions of cognitive-behavioral therapy, which…

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

TuesdayMay 10, 2022 3:27 pm

Survey Discovers That Psilocybin Is Relatively Safe Drug

Findings from a large survey propose that psilocybin is a relatively safe drug, with less than 1% of users of psilocybin mushrooms seeking emergency medical care after consumption. The survey’s findings, which also propose that adverse incidents resulting in emergency medical care are often psychological in nature and can be resolved in 24 hours, were reported in the “Journal of Psychopharmacology.” Psilocybin, which is the active ingredient found in hallucinogenic mushrooms, is known to induce a mind-altering state when consumed. While this compound is considered safe in comparison to other psychoactive substances, it can still cause adverse reactions such as…

MondayMay 09, 2022 1:52 pm

3 Psychedelic Documentaries You Can Watch on YouTube

New articles on psychedelic substances and their numerous uses in the field of medicine are being published every day in different parts of the world. As researchers discover more about psychedelics and the numerous benefits they hold, interest in these substances is growing. If you aren’t keen on reading medical journals to learn more about psychedelics but you’d still like to know more, here are some psychedelic documentaries you can watch on YouTube. True Hallucinations This experimental film, which is almost three hours long, is a tribute to the late philosopher Terence McKenna. McKenna spoke on and wrote about various…

FridayMay 06, 2022 12:18 pm

New Psychedelic Therapy Center Launched in Texas

Data from the National Institute on Drug Abuse shows that millions of individuals in America have already battled or will battle addiction to drugs, with 85% of them relapsing within one year of treatment. A recently launched program is hoping to lower this number significantly. The program, which was launched in Austin, Texas, will be administering ketamine therapy to eligible patients. The center, which has been christened Within, plans to combine psychedelic medicine with functional wellness and holistic healing in the treatment of addictions and mental disorders, including depression, post-traumatic stress disorder and substance abuse. Ryan Saldanha, a resident of…

FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

ThursdayMay 05, 2022 2:19 pm

Tesla CEO Elon Musk Believes Psychedelics Are Better Than Pharmaceutical Medications

Tesla CEO Elon Musk recently stated on Twitter that psychedelic substances and other plant-based drugs were effective as treatments for a number of mental health conditions. Musk has in the past smoked a joint during a livestream video. The tweet in question is an excerpt from a conversation between a pair of Twitter users, one of whom referred to a feature on the New York Times, which discussed Adderall. The other user replied to the tweet, noting that prescribed psychedelic drugs would soon replace selective serotonin reuptake inhibitors (SSRIs) and amphetamines, probably in the next decade. SSRIs are antidepressants commonly…

WednesdayMay 04, 2022 3:40 pm

Studies Find Link Between ADHD, Fibromyalgia

Various studies have found a link between fibromyalgia and ADHD, with some urging clinicians to evaluate the presence of attention deficit hyperactivity disorder (ADHD) in individuals who have a history of fibromyalgia. ADHD is a condition characterized by persistent impulsivity, hyperactivity, impaired concentration and inattention, as well as disorganized behavior, anxiety and emotional instability. The CDC estimates that while more than 8% of children have been diagnosed with this condition thus far, less than 1% of adults have received the same consideration. Fibromyalgia is a chronic pain disorder linked to modified activity of the neurotransmitters involved in pain sensitivity, with…

TuesdayMay 03, 2022 3:52 pm

Research Finds That Mushrooms May Have Their Own Language

New research has found that mushrooms have their own language that they use to talk to each other. The study, which was conducted by Professor Andrew Adamatzky of the University of the West of England, published its findings in the “Royal Society.” For their study, the researchers in Adamatzky’s laboratory focused on four different fungi: caterpillar, ghost, split gill and enoki fungi. They monitored the electrical signals that fungi send to each other via the underground tubes that connect them in a fungal colony, known as hyphae. The researchers then analyzed these signals, discovering that the signals pulsed in patterns…

TuesdayMay 03, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event

Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B In the United States, the company operates the country’s largest chain of ketamine (anesthesia-related medication) clinics for wellness therapies Delic Co-founder and CEO Matt Stang will continue his outreach to investors and other potential sources of industry financing when he presents an overview of the company’s operations and its outlook for the coming…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000